KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $137.9 million.

  • West Pharmaceutical Services' Income towards Parent Company rose 439.06% to $137.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.2 million, marking a year-over-year decrease of 90.98%. This contributed to the annual value of $478.0 million for FY2024, which is 1697.06% down from last year.
  • As of Q3 2025, West Pharmaceutical Services' Income towards Parent Company stood at $137.9 million, which was up 439.06% from $126.8 million recorded in Q2 2025.
  • West Pharmaceutical Services' 5-year Income towards Parent Company high stood at $183.0 million for Q2 2022, and its period low was $86.4 million during Q1 2025.
  • Moreover, its 5-year median value for Income towards Parent Company was $134.3 million (2023), whereas its average is $137.5 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Income towards Parent Company soared by 12075.72% in 2021, and later plummeted by 3243.06% in 2022.
  • Over the past 5 years, West Pharmaceutical Services' Income towards Parent Company (Quarter) stood at $147.7 million in 2021, then plummeted by 32.43% to $99.8 million in 2022, then surged by 33.97% to $133.7 million in 2023, then dropped by 4.19% to $128.1 million in 2024, then increased by 7.65% to $137.9 million in 2025.
  • Its Income towards Parent Company was $137.9 million in Q3 2025, compared to $126.8 million in Q2 2025 and $86.4 million in Q1 2025.